Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

ABSTRACT:

Background

Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in this population.

Methods

We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations. Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or place

SUBMITTER: Stone RM 

PROVIDER: S-EPMC5754190 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature